Friday 6 November 2026 Export SNY’s income statement to Excel — free account

Sanofi

SNY Healthcare Drug Manufacturers General

Sanofi’s revenue for fiscal 2025 (year ended December 2025) was $52.9 billion, up 10.3% from fiscal 2024.

Revenue: +13.9%
EPS: +8.21%
Free cash flow: +99.6%
Total debt: −11.2%

Quarter to September 2026, against a year earlier

Dividend growth 3 yrs

46.81 0.66 −1.39%

Follow SNY

Alert me

Market cap: $111.8B
P/E: 23.2×
Fwd P/E: —
Dividend yield: 5.18%
F-score: 7/9
Altman Z: 2.50
Beneish M: −2.63
Dividend safety: 54/100

Overview

Sanofi (SNY) Price to free cash flow

Alert me on Price to free cash flow

As of 5 November 2026, Sanofi (SNY) trades at a price to free cash flow of 6.7×. Over the past ten years it has ranged from 4.4× (April 2024) to 14.4× (November 2025); the current reading is higher than 41% of that period. That is below the Drug Manufacturers General industry median of 21.3× and below the Healthcare sector median of 21.1×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/SNY/price-to-free-cash-flow" width="100%" height="360" style="border:0" loading="lazy" title="Sanofi price to free cash flow, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/SNY/metrics/price-to-free-cash-flow">Sanofi (SNY) price to free cash flow — stockrow.com</a></p>

Period	Price to free cash flow	Change
FY2025	6.4×	8.14%
FY2024	5.9×	21.57%
FY2023	4.8×	1.68%
FY2022	4.8×	(29.72%)
FY2021	6.8×	(15.59%)
FY2020	8.0×	9.35%
FY2019	7.3×	27.15%
FY2018	5.8×	(9.05%)
FY2017	6.3×	(16.33%)
FY2016	7.6×	(15.47%)

Period	Price to free cash flow	Change
Sep 2026	5.9×	(15.79%)
Jun 2026	7.0×	12.58%
Mar 2026	6.2×	(1.90%)
Dec 2025	6.4×	(51.09%)
39 more quarters	Free account

Against its own ten years

Low 4.4× High 14.4×

Ten-year median 7.1×

Current reading's percentile 41

Company	Price to free cash flow
SNY Sanofi	6.7×
GSK GSK PLC Sponsored ADR compare	11.4×
BMY Bristol Myers Squibb Company compare	13.9×
GILD Gilead Sciences, Inc. compare	15.1×
PFE Pfizer Inc. compare	15.5×
NVS Novartis AG compare	21.7×
NVO Novo Nordisk A/S compare	23.5×
AMGN Amgen Inc. compare	27.3×
AZN AstraZeneca PLC compare	45.8×
Drug Manufacturers General industry median	21.3×
Healthcare sector median	21.1×
Market median	14.1×

What Price to free cash flow is

Price to Free Cash Flow Ratio shows how much investors pay for each dollar of cash a company generates after its capital spending.

Stock Price ÷ ((Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM)) ÷ (Shares (Basic, Weighted) (latest quarter)))

The full definition of Price to free cash flow →

Sanofi (SNY) Price to free cash flow

Price to free cash flow, daily

Annual newest first

Quarterly newest first

Against its own ten years

Price to free cash flow against peers

What Price to free cash flow is

More on SNY

Price to free cash flow, daily

Annual newest first

Quarterly newest first

Against its own ten years

Price to free cash flow against peers

What Price to free cash flow is

More on SNY

Stockrow Weekly